Drug Trial Radar · NCT04031742
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Sep 29, 2019
Primary completion
Dec 30, 2021
Study completion Dec 30, 2021
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate safety and efficacy of IBI306 in subjects with homozygous familial hypercholesterolemia.
Conditions
- Homozygous Familial Hypercholesterolemia
Interventions
IBI306Biological
Administered by subcutaneous injection
IBI306Biological
Administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C).Time frame: Baseline and Week 12
- Part 2: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)Time frame: Baseline and Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.